Xenomycins

The Xenomycin family of compounds has a broad range of potential applications as antimicrobial and anti-fungal agents. Xenomycins are in preclinical development through our Panacela Labs, Inc. subsidiary.

Xenomycins target basic microbial transcription and replication by binding the DNA of pathogens in a way (intercalating), which does not affect similar functions in mammalian cells.

Preclinical studies demonstrated efficacy of these compounds against parasites causing candidiasis, malaria, trypanosomiasis, and Chagas disease, including those with demonstrated resistance to other drugs.